PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - CALGB-80702
LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC) Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients Innocenti, F , Jiang, C , Sibley, A B , Denning, S , Etheridge, A S ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - C80405
Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio Seymour, L. K. , Teuff, G. Le , Tsao, M. , Brambilla, E. ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-150802 , CALGB-9633
CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy Venook, A. , Niedzwiecki, D. , Lenz, H. , Mahoney, M. , Innocenti, F. ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
